JPMorgan Chase & Co. Raises Holdings in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

JPMorgan Chase & Co. raised its holdings in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPTFree Report) by 58.7% during the third quarter, HoldingsChannel reports. The fund owned 9,770 shares of the company’s stock after purchasing an additional 3,612 shares during the quarter. JPMorgan Chase & Co.’s holdings in ClearPoint Neuro were worth $110,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Barclays PLC increased its position in shares of ClearPoint Neuro by 24.3% during the 3rd quarter. Barclays PLC now owns 5,674 shares of the company’s stock valued at $64,000 after purchasing an additional 1,109 shares during the last quarter. Geode Capital Management LLC boosted its position in ClearPoint Neuro by 1.5% during the third quarter. Geode Capital Management LLC now owns 287,294 shares of the company’s stock valued at $3,222,000 after buying an additional 4,170 shares during the period. Conway Capital Management Inc. bought a new position in shares of ClearPoint Neuro during the third quarter valued at about $1,586,000. XTX Topco Ltd increased its holdings in shares of ClearPoint Neuro by 53.0% in the third quarter. XTX Topco Ltd now owns 19,900 shares of the company’s stock worth $223,000 after buying an additional 6,890 shares during the period. Finally, Verition Fund Management LLC bought a new stake in shares of ClearPoint Neuro in the 3rd quarter valued at about $123,000. Hedge funds and other institutional investors own 30.08% of the company’s stock.

ClearPoint Neuro Price Performance

NASDAQ:CLPT opened at $17.46 on Monday. The firm has a market capitalization of $481.55 million, a price-to-earnings ratio of -25.30 and a beta of 1.01. The business has a 50 day simple moving average of $15.25 and a 200-day simple moving average of $12.51. ClearPoint Neuro, Inc. has a 1 year low of $5.11 and a 1 year high of $19.00.

ClearPoint Neuro (NASDAQ:CLPTGet Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.01). ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. The firm had revenue of $8.12 million for the quarter, compared to analysts’ expectations of $8.07 million. During the same quarter in the prior year, the business posted ($0.20) EPS. As a group, analysts expect that ClearPoint Neuro, Inc. will post -0.66 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on CLPT. Lake Street Capital upped their price objective on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, January 21st. B. Riley lifted their price objective on ClearPoint Neuro from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th.

View Our Latest Stock Report on CLPT

About ClearPoint Neuro

(Free Report)

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.

Recommended Stories

Want to see what other hedge funds are holding CLPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ClearPoint Neuro, Inc. (NASDAQ:CLPTFree Report).

Institutional Ownership by Quarter for ClearPoint Neuro (NASDAQ:CLPT)

Receive News & Ratings for ClearPoint Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ClearPoint Neuro and related companies with MarketBeat.com's FREE daily email newsletter.